Effect of ethanolic extract of *Cryptolepis sanguinolenta* stem on *in vivo* and *in vitro* glucose absorption and transport: Mechanism of its antidiabetic activity

A. F. Ajayi, R. E. Akhigbe, O. M. Adewumi¹, L. O. Okeleji, K. B. Mujaidu, S. B. Olaleye²

Department of Physiology, College of Health Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, ¹Department of Plant Biology, Faculty of Sciences, University of Ilorin, Ilorin, ²Department of Physiology, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria

**ABSTRACT**

**Objective:** Extracts from various morphological parts of *Cryptolepis sanguinolenta* are widely used traditionally in folklore medicine in many parts of the world for the management, control, and/or treatment of a plethora of human ailments, including diabetes mellitus. In order to scientifically appraise some of the ethnomedical uses of *Cryptolepis sanguinolenta*, the present study was undertaken to investigate its influence at varying doses on intestinal glucose absorption and transport in relation to its hypoglycemic and hypolipidemic effects in rat experimental paradigms.

**Materials and Methods:** The animals used were divided into four groups. Control animals received 2 ml of distilled water, while treated groups received 50, 150, and 250 mg/kg bw of *Cryptolepis sanguinolenta* extract per oral respectively daily for 21 days. **Results:** *Cryptolepis sanguinolenta* led to a significant decrease in glucose transport and absorption. It also caused significant reductions in plasma glucose, total cholesterol, triglyceride, and LDL cholesterol. Biochemical changes observed were suggestive of dose dependence. Histopathological studies also showed increased sizes of β cells of the pancreas. **Conclusion:** The findings in these normoglycemic laboratory animals suggest that *Cryptolepis sanguinolenta* has hypoglycemic and hypolipidemic activities, possibly by reducing glucose absorption and transport, and enhancing the structural and functional abilities of the β cells. This is the first study to report the effect of *Cryptolepis sanguinolenta* on intestinal glucose absorption. This effect could be attributed to its major bioactive principle, cryptolepine, an indoloquinoline alkaloid. This study thus lends credence to the use of *Cryptolepis sanguinolenta* in the management of diabetes mellitus.

**Key words:** β cells, *Cryptolepis sanguinolenta*, diabetes, glucose, lipid

**INTRODUCTION**

Diabetes mellitus (DM) is a clinical syndrome characterized by inappropriate hyperglycemia caused by absolute or relative deficiency of insulin or resistance to the action of insulin at the cellular level. DM is one of the most common endocrine and metabolic disorders of the 21st century, and a major threat to healthcare worldwide.¹ DM is associated with alterations in carbohydrate, protein, and lipid metabolism.²,³ World Health Organization (WHO) suggests that the global population is in the midst of a diabetes epidemic and the number of cases for diabetes that is currently 171 million is predicted to reach 366 million by the year 2030.⁴ Majority of patients with diabetes have type 2 or non-insulin-dependent diabetes while the remainder has type 1 or insulin dependent diabetes. Although the two types have distinct pathogenesis, hyperglycemia and various life-threatening complications resulting from long-term hyperglycemia are the most common features.⁵ The
complications of diabetes are associated with elevated levels of plasma triglycerides and cholesterol (due to an increase in plasma concentration of VLDL and LDL). These play significant roles in the accelerated development of arteriosclerotic vascular disease.\cite{6,7} Since the major cause of diabetes is a defect in insulin, it is then required to develop pharmacological agents that could prevent beta-cell destruction or promote beta cell regeneration in the pancreas.

Drugs used in the management of DM are not without side effects. This has led to the continued search for new antidiabetic drugs in this folklore/Ayurvedic medicine with the aim of getting less expensive and safer management options. A plant commonly used for its antidiabetic activity is Cryptolepis sanguinolenta containing cryptolepine, an indoloquinoline alkaloid.

Cryptolepis sanguinolenta is a thin-stemmed twining and scrambling shrub up to 8 m long, containing yellow-orange juice which becomes red upon drying. It is a member of the family Apocynaceae (subfamily: Periplocoideae). The plant is native to West Africa and is found in countries like Ghana, Cote d'Ivoire, Guinea, Guinea-Bissau, Mali, Nigeria, Senegal, Sierra Leone, Angola, Congo, Uganda, and Cameroon. It is a medicinal plant used by some traditional herbalist in the treatment of fever, urinary, and upper respiratory tract infections. \cite{8} The use of this plant as a medical therapy has increased as it has been proposed that the root and leaf extracts have hypotensive, antipyretic, anti-inflammatory, antidiarrhoecal, in vitro antibacterial and antimalarial effects. \cite{9} It is commonly called nibima, Kadeg, gangaman, or yellow-dye root. \cite{8} It is called paran papa in the Yoruba-speaking areas of Nigeria.

Studies have documented the antidiabetic potentials of Cryptolepis sanguinolenta;\cite{10-12} however, there is still a dearth of information in the open scientific literature on the studies that evaluated the effect of the Cryptolepis sanguinolenta on intestinal glucose absorption and transport. Therefore, we decided to bridge this gap and provide scientific information on the role of glucose absorption and transport as a mechanism of the antidiabetic activity of Cryptolepis sanguinolenta.

**MATERIALS AND METHODS**

**Plant materials**

Stem of Cryptolepis sanguinolenta were obtained from Ojurin Akobo-Olorunda road, Oyo, Oyo state, Nigeria. The plant was authenticated by Ugbofu A, Chukwuma E.C, and Shasanya O.S of the Forest Herbarium, Ibadan, Nigeria, where a voucher specimen (FHI 108847) was deposited. The dried stem was broken into pieces and beaten into smaller sizes using mortar and pestle before being pulverized. The powder formed after pulverization was weighed and stored until required.

**Preparation of ethanolic extract of Cryptolepis Sanguinolenta**

Extract of cryptolepine sanguinolenta was prepared as described by Ansah et al.,\cite{13} with some modifications. Briefly, 1,226 g of the powdery stem was dissolved in 4.81 of 65% ethanol. The mixture was dissolved to stand for 48 hours. The extract was filtered using clothen sieve and was evaporated at 40°C. From the viscous solution gotten, a 0.1 M solution of extract was prepared by dissolving 5 ml of viscous solution of extract in 45 ml of distilled water.

**Animals**

Wistar albino rats weighing 130–170 g were obtained from the Animal House of the Department of Physiology, Ladoke Akintola University of Technology, Ogbomoso, Nigeria. The rats were housed in standard plastic cages, with 12-hour light–dark cycle. The animals were fed with rat chow and water without restriction. The rats were acclimatized for 2 weeks. They were assigned into four groups.\cite{14} Control rats did not receive any extract. Animals in the test groups (1, 2, and 3) were orally fed using oral cannula once daily with 50 mg/kg, 150 mg/kg, and 250 mg/kg body weight of extract respectively. Administration of the extract was carried out for 21 days.

All animals received humane care in compliance with the institution's guideline and criteria for humane care as outlined in the National Institute of Health Guidelines for the Care and Use of Laboratory Animals.

**Collection of blood samples**

The blood samples used for the glucose test were obtained by pricking the tip of the tail of the rat. The blood samples used for the lipid profile were got via cardiac puncture. The blood was collected into EDTA bottles, spinned with centrifuge for 5 minutes, and the plasma was separated for lipid profile analysis.

**Blood glucose analysis**

The animals were fasted for a 12-hour period and the initial fasting blood glucose were taken for the four groups on the day one of the experiment using glucometer. The blood taken from the tail tip was placed on designated spot on glucometer strip connected to the glucometer. The final blood glucose of the rats was taken after about 24-hour fasting period after administering the extract for 21 days.

**Intestinal absorption in vivo**

After an overnight fast, each animal was anesthetized...
density lipoprotein (LDL) was calculated using Friedewald’s equation which is given as:

\[ LDL = TC - HDL - \frac{TG}{50} \]

Histopathological study
After the 21st day, the animals were killed through cervical dislocation and opened up. The pancreas were collected and preserved in 10% formalin. Tissue processing was carried out by autotechnique. Five micrometer thick sections were prepared and mounted on slides and stained with hematoxylin and eosin (H&E). Stained sections were morphologically evaluated and the microphotograph was taken.

Statistical analysis
Data were expressed as mean ± standard error of mean (n=5). Values for blood glucose before and after treatment were analyzed using a paired t-test, while those for the lipid profile were analyzed using an unpaired t-test to compare each test group and control. Analysis of variance, ANOVA, was used to compare values across all groups. All analyses were done using the Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA). Differences in mean values were considered significant at P<0.05.

Results
There were significant (P<0.05) reductions in the blood glucose concentrations in the treated groups [Figure 1]. There were also significant (P<0.05) reductions in the fasting plasma levels of TC, TG, and LDL cholesterol in the treated groups. The changes seen were dose related. HDL-cholesterol was significantly increased (P<0.05) in a dose-dependent manner.

Similarly, intestinal glucose absorption and transport were also significantly (P<0.05) reduced in all treated animals in a dose-dependent manner [Figures 2 and 3].

A microscopic study showed an increase in the sizes of Islet of Langerhans and altered β-cells counts [Figure 4].

Discussion
Along with hyperglycemia and abnormalities in serum lipids, diabetes is usually associated with microvascular and macrovascular complications which are the major causes of morbidity and mortality in diabetic individuals. Diabetes can be managed by exercise, diet, and drugs. Hypoglycemic drugs are either too expensive, or possess undesirable side effects. Therefore, the search for more effective and safer hypoglycemic agents from plants and other natural sources has continued to be an area of interest for many researchers. Plants are a major source of drugs...
Ajayi, et al.: Cryptolepis sanguinolenta and glucose

and many currently available drugs have been directly or indirectly obtained from botanicals.[17] Phytochemical screening helps to reveal the chemical constituents of the plant extract and the one that predominates over the others. It is also used to search for bioactive agents for starting products used in the synthesis of some useful drugs.[18] Results from the phytochemical analyses of Cryptolepis sanguinolenta have shown the presence of Cryptolepine, an indoloquinoline alkaloid, as its major alkaloids.[19-22] Crude extracts of Cryptolepis sanguinolenta and their fractions, as well as indoloquinoline alkaloids isolated from the plant, have been shown to have antidiabetic activity.[10,11,13,23] Various studies have linked its antidiabetic activity to its effects on pancreas and glucose transport, but none has associated it with glucose intestinal absorption. This study thus documents the influence of Cryptolepis sanguinolenta on intestinal glucose absorption and transport in relation to its antihyperglycemic potentials.

In the present study, we noticed dose-related reductions in plasma glucose in Cryptolepis sanguinolenta-treated normoglycemic rats. Similarly, the extract reduced total cholesterol, triglyceride, and LDL cholesterol in treated rats when compared to the control. Lipids play an important role in the pathogenesis of diabetes mellitus. This is in consistence with previous studies.[10,11,13,23] The level of serum lipids is usually raised in diabetes, and such an elevation represents a risk factor for coronary heart
diseases. The alterations in plasma glucose and lipid profile seen in treated animals could be beneficial in preventing diabetic complications as well as in improving lipid metabolism in diabetics.

The findings of this experimental animal study also showed that *Cryptolepis sanguinolenta* significantly depressed intestinal glucose absorption and transport in the normoglycemic rats in a dose-related manner. The depression of glucose absorption and transport observed may account for the antihyperglycemic effect of the botanical with resultant enhancement of lipid profile. This is in tandem with previous study that reported that *Cryptolepis sanguinolenta* reduced glucose transport and caused hypoglycemia.

Observations in this study also showed that *Cryptolepis sanguinolenta* treatment led to increased β cell sizes. This probably enhanced insulin activities. The fundamental mechanism underlying hyperglycemia involves overproduction (excessive hepatic glycogenolysis and gluconeogenesis) and decreased utilization of glucose by the tissues. The hypertrophied β cells might be responsible for enhanced insulin production and activity with resultant hypoglycemia. The reduction in the blood glucose levels of the treated animals confirms the hypoglycemic effect of *Cryptolepis sanguinolenta* stem extract. The findings in this study revealed that the extract acted via several mechanisms such as slowing down the absorption and transport of glucose from the guts, and increasing insulin production by the pancreas from possibly the hypertrophied β cells. These mechanisms of action corroborates other mechanisms previously reported such as increase glucose uptake by 3T3-L1 cells and enhancement of insulin-mediated glucose disposal.

The hypoglycemic activity of the extract seen in the present study could be attributed to its alkaloid constituents. Alkaloids have been reported to improve insulin resistance in mice and high fat-fed rats. They can activate AMP-activated protein kinase in 3T3-L1 adipocytes and L6 myotubes and facilitate GLUT4 translocation in L6 myotubes in a phosphatidylinositol 3-kinase-independent manner. They have also been reported to promote glucose uptake in HepG2 and 3T3-L1 cells independent of insulin action. In addition, it effectively inhibits sucrase and maltase activities to the same extent as acarbose does in Caco-2 intestinal cells and possibly inhibit α-glucosidase activities to reduce glucose absorption. It has also been documented to significantly reduce serum IL-6 with insulin sensitivity improvement. This study provides a new mechanism of action of the hypoglycemic activity of alkaloids-containing *Cryptolepis sanguinolenta* stem extract.

**Conclusion**

Based on our findings, we lend credence to the use of *Cryptolepis sanguinolenta* in the management of diabetes mellitus. The hypoglycemic activity of *Cryptolepis sanguinolenta* is associated with its influence to reduce intestinal glucose absorption and transport. It is also related to its hypertrophic effect on β cells.

**References**

1. Adewole Stephen O, Ojewole John AO. Protective effects of *Annona muricata* Linn. (Annonaceae) leaf aqueous extract on serum lipid profiles and oxidative stress in hepatocytes of streptozotocin-treated diabetic Rats. Afr J Tradit Complement Altern Med 2006;8:30-41.
2. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Geneva, Switzerland: WHO; 1999.
3. Scoppola A, Montecchi FR, Mezinger G, Lala A. Urinary mevalonate excretion rate in type 2 diabetes: Role of metabolic control. Artherosclerosis 2001;156:357-61.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
5. Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L. Antidiabetic effects of panax ginseng berry extract and the identification of an effective component. Diabetes 2002;51:1851-8.
6. Cheng A, Folson J, Ma D, Arnett B, McGovean, Eddelstedt J. Plasma fatty acid composition and 6 years incidence of hypertension in middle-aged adults: The atherosclerosis risk in community (ARIC) study. Am J Epidemiol 1991;150:492-500.
7. Ganong W. Review of Medical Physiology. 18th ed. San Francisco: Appleton and Lange; 1997. p. 31-33.
8. McGuffin M, Kartesz JT, Leung AY, Tucker AO. Herbs of commerce, 2nd ed. 2000.
9. Iwu M. Handbook of African medicinal plants. Boca Raton, FL: CRC Press; 1993.
10. Bierer DE, Dubenko LG, Zhang P, Lu Q, Imbach PA, Garofalo AW, et al. Antihyperglycemic activities of cryptolepine analogues: An ethnotobanatological lead structure isolated from *Cryptolepis sanguinolenta*. J Med Chem 1998;41:2754-64.
11. Bierer DE, Fort DM, Mendez CD, Luo J, Imbach PA, Dubenko LG, et al. Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: Its isolation from *Cryptolepis sanguinolenta*, synthesis, and in vitro and in vivo activities. J Med Chem 1998;41:894-901.
12. Luo J, Fort DM, Carlson TJ, Noamesi BK, nii-Amon-Kotei D, King SR, et al. *Cryptolepis sanguinolenta*: An ethnotobanatological approach to drug discovery and the isolation of a potentially useful new antihyperglycaemic agent. Diabet Med 1998;15:367-74.
13. Ansah C, Mboafa EA, Woode E, Opoku-Okrach C, Owreed WK. Toxicological evaluation of the anti-malarial herb *Cryptolepis sanguinolenta* in rodents. J Pharmacol Toxicol 2008;3:335-43.
14. Akihage RE, Ije SF, Afolabi AO, Oyequipi PI, Ajoa FO, Ajayi PA. Water balance and serum levels of some electrolytes in oral contraceptive-treated female wistar rats. J Med Sci 2008;8:591-4.
15. Virella-Lopes MF, Virella G. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Frontiers Biosc 2003;8:750-68.
16. Krishna B, Nammi S, Kota MK, Krishna Rao RV. Evaluation of hypoglycaemic and antihyperglycaemic effects of *Datura metel* Linn.
seeds in normal and alloxan induced diabetic rats. J Ethnopharmacol 2004;9:95-8.

17. Yakubu MT, Akanji MA, Nafiu MO. Anti-diabetic activity of aqueous extract of Cochlospermum planchonii root in alloxan-induced diabetic rats. Cameroon J Exp Biol 2010;6:91-100.

18. Yakubu MT, Akanji MA, Oladiji AT. Aphrodisiac potentials of the aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male albino rats. Asian J Androl 2005;7:399-404.

19. Rauwald HW, Kober M, Mutschler E, Lambrecht G. Cryptolepis sanguinolenta: antimuscarinic properties of cryptolepine and the alkaloid fraction at M1, M2 and M3 receptors. Planta Med 1992;58:486-8.

20. Lisgarten JN, Coll M, Portugal J, Wright CW, Aymami J. The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites. Nat Struct Biol 2001;9:57-60.

21. Charles A, Gooderham NJ. The popular herbal antimalarial, extract Cryptolepis sanguinolenta: Is potently cytotoxic. Toxicol Sci 2002;70:245-51.

22. Bugyei KA, Boye GL, Addy ME. Clinical efficacy of a tea-bag formulation of Cryptolepis Sanguinolenta root in the treatment of acute uncomplicated falciparum malaria. Ghana Med J 2010;44:3-9.

23. Bamgbose SO, Noamesi BK. Studies on cryptolepine II. Inhibition of carrageenan-induced oedema by cryptolepine. Planta Med 1981;41:392-6.

24. Mironava MA, Klein RL, Virella GT, Lopes-Virella MF. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 2000;49:1033-49.

25. Latner A. Clinical Biochemistry. Philadelphia: Saunders; 1958. p. 48.

26. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin End Metab 2008;93:2559-65.

27. Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, et al. Effects of berberine on glucose metabolism in vitro. Metabolism 2002;51:1439-43.

28. Zhou L, Yang Y, Wang X, Liu S, Shang W, Yuan G, et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 2007;56:405-12.

29. Pan GY, Huang ZJ, Wang GJ, Fawcett JP, Liu XD, Zhao XC, Sun JG, Xie. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med 2003;69:632-6.

30. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 2005;28:1769-78.

31. Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res 2005;66:265-75.

32. Zuo F, Nakamura N, Akao T, Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos 2006;34:2064-72.